华海药业(600521.SH)：卡络磺钠注射液获得药品注册证书

Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received the drug registration certificate for Carbetocin Injection from the National Medical Products Administration, indicating a significant regulatory approval for the company’s product in the market [1] Group 1: Product Information - Carbetocin Injection is indicated for bleeding diseases in the urinary system, upper digestive tract, respiratory tract, and gynecology [1] - The product shows notable efficacy in treating urinary system conditions and can also be used for the prevention and treatment of surgical bleeding [1]